Despite the recently reported efficacy of daratumumab monotherapy for patients with relapsed or refractory multiple myeloma, outcomes in real practice following daratumumab monotherapy have yet to be investigated. A multi-center retrospective study of 16 Korean patients receiving daratumumab monotherapy for relapsed or refractory multiple myeloma was conducted. The overall response rate was 56.3%. Three patients with creatinine clearance <30 ml/min even achieved an overall response. The median progression-free survival was 2.7 months with 28.9% (95% CI, 9.0-52.8) of 6-month progression-free survival. All infusion-related reactions, including ≥Grade 3 back pain (6.3%) and dyspnea (6.3%), were manageable. The most common hematologic and nonhematological adverse events were anemia (62.5%) and upper respiratory infection (43.8%). ≥Grade 3 bacterial infectious adverse events were identified, including upper and lower respiratory infection (12.5% and 18.8%) and death following sepsis (6.3%). We observed acceptable © The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 92 outcomes of daratumumab monotherapy on relapsed or refractory multiple myeloma patients including even a few subjects with high comorbidity, despite relatively frequent infectious adverse events.
Introduction
Advances in novel therapies including proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) have improved outcomes in patients with multiple myeloma (MM) (1) (2) (3) . Nevertheless, treatment options for patients with MM whose disease has relapsed or is refractory (RRMM) to IMiDs (lenalidomide, thalidomide, or pomalidomide) and/or PIs (bortezomib, carfilzomib or ixazomib) are limited, and prognosis in these cases is dismal (4, 5) .
Daratumumab is a first-in-class, anti-CD38 human immunoglobulin (Ig) G1 monoclonal antibody that was recently approved as monotherapy for patients with MM who received three or more prior treatments with a PIs or with an IMiDs, and patients who are double-refractory to proteasome inhibitors and immunomodulatory drugs (6) . As CD38 is uniformly and ubiquitously expressed on MM cells (7, 8) , targeting CD38 with daratumumab monotherapy (DM) is relevant to the treatment of MM. DM has demonstrated promising anti-MM activity together with a manageable safety profile across Phase 1 and 2 clinical trials (GEN501 and SIRIUS) in patients with RRMM (9, 10) .
Aside from the aforementioned Phase 1 and 2 clinical trials, the treatment outcomes of DM for patients with RRMM in real clinical practice have yet to be investigated in Korea, or even in East Asia. After approval of the emergency use of DM by the Ministry of Food and Drug Safety of Korea, 16 Korean patients were treated with DM provided by Korean Multiple Myeloma Working Party. This study aims to verify the clinical outcome of patients receiving DM in real clinical practice for the first time.
Materials and methods

Patients and material
Data from 16 patients with RRMM who received DM at nine university hospitals in the Republic of Korea between January 2017 and December 2017 were retrospectively collected. All patients received ≥2 prior lines of therapy for MM. Selection criteria of patients receiving DM were as follows: (1) patient who had received at least 3 prior lines of therapy including a PI and an IMiD; (2) patient whose disease was double refractory to a PI and an IMiD; or (3) patient who cannot use another PIs except for bortezomib due to insufficient coverage by Health Insurance Review & Assessment Service in Korea, and IMiDs owing to intolerance to dexamethasone whose dose is commonly combined with IMiDs. Based on clinician's discretion, this study included even patients with severe comorbidity including absolute neutrophil count <1 × 10 9 /L, hemoglobin <7.5 g/dL, platelet counts <50 × 10 9 /L, Eastern Cooperative Oncology Group (ECOG) performance ≥3 or severe renal compromised status, which were exclusion criteria of GEN501 or SIRIUS (9, 10) . Approval for this study was obtained from the Institutional Review Board of each multi-center.
Treatment procedure for daratumumab
Patients received DM intravenously with a dose of 16 mg/kg weekly for the first 8 weeks (Cycles 1 and 2), then every 2 weeks from 9 to 24 weeks (Cycles 3-6), then every four weeks thereafter (Cycles 7 and higher). The first infusion of daratumumab used a dilution volume of 1000 mL with an infusion rate of 50 mL/h. Second infusions used a dilution volume of 500 mL with the same infusion rate of 50 mL/h. Subsequent infusions following the first and second infusion were performed at dilution volumes of 500 mL with initial infusion rates of 100 mL/h. The infusion rate was increased in each case to 200 mL/hour in 50 mL/hour increments, if there were no infusion-related reactions (IRRs). To prevent IRRs, patients received premedication one hour prior to administration of daratumumab as follows: intravenous methylprednisolone 100 mg (or an equivalent long-acting corticosteroid) for the first two infusions, with subsequent doses of methylprednisolone potentially reduced to 60 mg at the discretion of the physician, in the absence of IRRs during the first and second infusions; oral antipyretics (paracetamol, 650-1000 mg); and an oral or intravenous antihistamine (diphenhydramine, 25-50 mg or equivalent).
Definition and statistical analyses
The response of daratumumab was evaluated according to the international myeloma working group response criteria (11) . Responders are indicated as the patients who achieved a partial response or better. The overall response rate (ORR) is defined as the ratio of responders to total patients. The Kaplan-Meier method was used to analyze time-to-event endpoints including progression-free survival (PFS) and overall survival. Severity of IRRs and adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03) (12) .
Results
Patients' characteristics
The median age was 69 years (range, 55-88 years). Upon initiation of daratumumab, poor performance status [ECOG performance score of 3 or more] was shown in one patient (No. #10) and severely impaired renal function (Creatinine clearance <30 mL/min) was shown in three patients (Nos. #3, #12 and #15). Extramedullary plasmacytoma was identified in three patients (Nos. #2, #7 and #12). All patients had been previously treated with bortezomib (n = 16, 100%), dexamethasone (n = 16, 100%), and some immunomodulatory drug including thalidomide (n = 11, 68.8%), lenalidomide (n = 15, 93.8%) or pomalidomide (n = 8, 50.0%). During the median 83.5 (range, 10.1-183.9) months from diagnosis to administration of daratumumab, 10 patients (62.5%) had received autologous stem cell transplantation. With a median four (range, 2-8) prior lines of therapy, 15 patients (93.8%) received more than three lines of therapy. Of all, 14 patients (87.5%) were refractory to the last line of therapy, and the median number of refractory drug was 4.5 (range, 2-10). Refractoriness to specific drugs was as follows: bortezomib in 10 patients (62.5%), lenalidomide in 10 patients (62.5%) and alkylating agents in 11 patients (68.8%). Among seven patients (43.8%) who were refractory to both bortezomib and lenalidomide, five patients (31.3%) were also refractory to pomalidomide (Supplementary Table 1 ). Other information on each patient is shown in Supplementary Table 2.
Response and survival outcome
As shown in Table 1 , with a median seven treatment cycles given to patients (range, 1-29), an overall response was shown in 9 of 16 patients [56.3% of ORR: 4 patients (25.0%) achieving complete response and 5 patients (31.3%) achieving partial response]. Of eight patients who relapsed or were refractory to more than two agents (of bortezomib, lenalidomide and pomalidomide), three achieved overall response (ORR: 37.5%). In three patients with extramedullary plasmacytoma, overall response was shown in one patient (ORR: 33.3%). Among four patients (Nos. #3, #10, #12 and #15) with poor renal function (creatinine clearance <30 mL/ min) or poor performance status (ECOG score ≥3), three patients (Nos. #3, #12 and #15) achieved overall response (ORR: 75.0%).
The median treatment duration was 10.0 (0.7-12.5) months. The median PFS was 2.7 (range, 0.7-11.1) months, the probability of 6-month-PFS was 28.9% (95% CI, 9.0-52.8). The median PFS of the seven non-responders was 2.7 months whereas that of responder was 7.4 months (P = 0.003). The 6-month overall survival rate was 74.0% (95% CI, 44.6-89.4). The median overall survivals were similar for responders (10.7 months) and non-responders (9.8 months) (Supplementary Figure) . [6.3%] ). All Grade 3 or higher non-hematologic AEs were associated with infection: two upper respiratory infections (14.3%, Nos. #1 and #15), three lower respiratory infections (21.4%, Nos. #1, #9 and #14) and one bacteremia (7.1%, No. #10). All Grade 3 or higher infectious AEs in organisms were suspected to be caused by bacteria including Streptococcus pneumoniae (N = 1), Pseudomonas aeruginosa (N = 1), Staphylococcus aureus (N = 1), Escherichia coli (N = 1) and unknown (N = 2, suspicious bacterial pneumonia on imaging).
Infusion-related reactions and adverse events
Discussion
In this study, we observed that daratumumab produced a 56.3% ORR, which is substantially higher than the ORRs of 36% in GEN501 and 29% in SIRIUS studies, respectively (9, 10) . This discrepancy may have resulted from the different levels of refractoriness to prior treatment between the prior studies and the current study. The number of patients who had been heavily treated and relapsed and/or who were refractory MM to both bortezomib and lenalidomide was relatively lower in this current study (seven patients, 43.8%) compared with GEN501 (64%) or SIRIUS (82%). Moreover, a subgroup consists of patients presenting after relapse or refractory to more than two novel agents (of bortezomib, lenalidomide and pomalidomide) had an ORR 37.5%, which was comparable with that in GEN501 or SIRIUS. Like most research studies that focus on the effectiveness of disease-specific interventions and exclude patients with high comorbidity (13), both GEN501 and SIRIUS also excluded patients with high comorbidity such as high-grade renal or heart failure, poor performance status or severe lung disease. However, the current study included patients with high comorbidity as it is easily encountered in real clinical practice for RRMM (14) . We observed an acceptable response rate, regardless of severe renal failure, while one patient with a poor performance status did unfortunately die at an early time point. This study reaffirms that DM is a relevant option for patients with RRMM, even for those with severe renal failure.
In line with the results of the safety profile demonstrated in GEN501 and SIRIUS, hematological AEs were a major concern Response cannot be assessed due to early death by sepsis during first cycle of daratumumab monotherapy. following DM. In addition, unlike previous reports, our study shows that infectious AEs, especially bacterial infections, are also an important consideration for DM. GEN501 reported that only 17% of patients developed upper respiratory tract infection, but there was no patient who experienced Grade 3 or higher upper respiratory tract infection. SIRIUS did not even describe any cases of upper respiratory tract infection after daratumumab because it did not commonly occur (<20%). However, the current study showed that upper respiratory infection was the most common non-hematological AEs and even Grade 3 or higher upper respiratory infection also occurred frequently. Other bacterial infectious Grade 3 or higher AEs, including lower respiratory infection and bacteremia, were also reported, although those AEs were not reported in GEN501 or SIRIUS. One patient, who showed both ECOG 3 performance and neutropenia when initiating DM, even died of sepsis following bacteremia. Toxicity profile of current study suggests that infectious complications should be considered when administering DM for RRMM in real practice.
The results of this study contain a number of limitations including the descriptive and retrospective design, and the small sample size. Any statistical analysis is therefore difficult to be performed due to low power. Despite these limitations, our data showed comparable efficacy of DM in Korean patients with RRMM. Infectious AEs might be another concern for MM patients receiving DM, in real clinical practice.
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